CYTO - Why Altamira Therapeutics Stock Is Racing Higher | Benzinga
Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares are trading higher Monday after the company announced that it has entered into a collaboration agreement with Univercells Group to evaluate the use of the company’s proprietary SemaPhore platform for the delivery of mRNA vaccines.
The Details:
Under the terms of the agreement, Univercells will test a proprietary mRNA vaccine delivered with Altamira’s SemaPhore nanoparticle platform. If the experiments are successful, the companies intend to discuss and negotiate a commercial agreement for the development and manufacturing of nanoparticle-based mRNA vaccines using Univercells’ production platform.
“We are thrilled to initiate this collaboration with Univercells to explore SemaPhore as a delivery vehicle for mRNA vaccines”, commented Covadonga Pañeda, PhD, Altamira’s COO.
“SemaPhore has shown to be an efficient delivery vehicle for therapeutic RNA in many different disease models. With this collaboration we will explore for the first time its potential utility ...